Date: 2013-09-04
Type of information: Initiation of preclinical development
phase: preclinical
Announcement: initiation of preclinical development
Company: XBiotech (USA - TX)
Product: True Human™ antibody therapy for methicillin resistant staphylococcus aureus (MRSA)
Action
mechanism: monoclonal antibody
Disease: methicillin resistant staphylococcus aureus (MRSA) infections
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On September 4, 2013, XBiotech announced that it has completed discovery and has begun pre-clinical development of a new True Human™ antibody therapy for methicillin resistant staphylococcus aureus (MRSA). The new antibody therapy is expected to be effective at neutralizing drug resistant staphylococcus infection by circumventing key immune evasion strategies of the bacteria, thereby facilitating natural clearance of the bacteria by the patient's own immune system. XBiotech reports that the MRSA antibody came out of its True Human™ antibody discovery program for identifying and cloning pharmacologically relevant antibodies from human donors. XBiotech expects this product candidate to enter human clinical trials next year.
